Mycoplasma Infections Clinical Presentation
- Author: Ken B Waites, MD; Chief Editor: Michael Stuart Bronze, MD more...
Typical symptoms can develop and persist over weeks to months and include flulike manifestations.
Symptoms may include the following:
- Generalized aches and pains
- Fever (usually ≤ 102°F)
- Cough - Usually nonproductive
- Sore throat (nonexudative pharyngitis)
- Chills but not rigors
- Nasal congestion with coryza
- General malaise
In very young children, upper respiratory tract manifestations may predominate, whereas in older children and adults, lower respiratory tract symptoms are more likely.
Physical findings can be quite variable. Patients typically do not appear toxic or severely ill, but some abnormalities may be apparent in a significant proportion of cases.
Physical findings include the following:
- Oropharyngeal inflammation
- Cervical adenopathy - Usually absent
- Erythematous tympanic membranes
- Maculopapular or urticarial rash
Chest auscultation in patients with pneumonia may demonstrate localized rhonchi and scattered moist rales, generally involving multiple lobes of the lung and sometimes accompanied by wheezes, with no signs of consolidation, egophony, or bronchial breathing.
In many persons, chest auscultative and percussive abnormalities are minimal to absent.
Extrapulmonary manifestations may occur in a minority of persons (see Complications).
This is a bacterial infection caused by M pneumoniae.
Muir MT, Cohn SM, Louden C, Kannan TR, Baseman JB. Novel toxin assays implicate Mycoplasma pneumoniae in prolonged ventilator course and hypoxemia. Chest. 2011 Feb. 139(2):305-10. [Medline].
Kannan TR, Provenzano D, Wright JR, Baseman JB. Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect Immun. 2005 May. 73(5):2828-34. [Medline].
Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains. Am J Respir Crit Care Med. 2010 Sep 15. 182(6):797-804. [Medline].
Hardy RD, Coalson JJ, Peters J, Chaparro A, Techasaensiri C, Cantwell AM. Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PLoS One. 2009. 4(10):e7562. [Medline].
Talkington DF, Waites KB, Schwartz S, Besser RE. Emerging from obscurity: Understanding pulmonary and extrapulmonary syndromes, pathogenesis, and epidemiology of human Mycoplasma pneumoniae infections. Scheld WM, Craig WA, Hughes JM, eds. Emerging Infections. Washington, DC: ASM Press; 2001. Vol 5: 57-84.
Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis. 1993 Aug. 17 Suppl 1:S37-46. [Medline].
Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997 Aug 11-25. 157(15):1709-18. [Medline].
Waites KB. New concepts of Mycoplasma pneumoniae infections in children. Pediatr Pulmonol. 2003 Oct. 36(4):267-78. [Medline].
Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006 May. 12 Suppl 3:12-24. [Medline].
Cunha BA. Pneumonia Essentials. 3rd ed. Royal Oak, MI: Physicians Press; 2010.
Cunha BA. Liver involvement with Mycoplasma pneumoniae community-acquired pneumonia. J Clin Microbiol. Jul/2003. 41(7):3456-7. [Medline].
Parchuri S, Cunha BA. Mycoplasma pneumoniae community-acquired pneumonia: Diagnostic usefulness of the agglutination-dissociation test. Infect Dis Pract. 2006. 30:550-1.
Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol. 2004 Sep. 11(5):862-7. [Medline].
Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol. 2005 May. 43(5):2277-85. [Medline].
Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS. Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol. 2008 Sep. 46(9):3116-8. [Medline].
Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009 May. 53(5):2160-2. [Medline]. [Full Text].
Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J. 2009 Aug. 28(8):693-6. [Medline].
Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009 Jul. 64(1):52-8. [Medline].
Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother. 2008 Oct. 52(10):3542-9. [Medline]. [Full Text].
Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006 Feb. 50(2):709-12. [Medline].
Klausner JD, Passaro D, Rosenberg J, et al. Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis. 1998 Jan. 177(1):161-6. [Medline].
Ou G, Liu Y, Tang Y, You X, Zeng Y, Xiao J, et al. In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae. Hippokratia. 2015 Jan-Mar. 19 (1):57-62. [Medline].